<DOC>
	<DOC>NCT00699153</DOC>
	<brief_summary>Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.</brief_summary>
	<brief_title>Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Subjects at least 18 years of age Subjects who have the ability to understand and sign an informed consent form and provide Health Insurance Portability and Accountability Act (HIPAA) authorization. Subjects who are candidate for routine, uncomplicated cataract surgery. Subjects who are not of childbearing potential or subjects who have a negative urine pregnancy test result at screening. Subjects must be willing and able to comply with all treatment and follow up procedures. Subjects who have known hypersensitivity or contraindication to the study drug or its components. Subjects who have a history or presence of chronic generalized systemic disease that the investigator feels might increase the risk to the subject or compound the result of the study. Subjects who have a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment or followup. Subjects with elevated intraocular pressure (&gt;/= 21 mm Hg), uncontrolled glaucoma, or being treated for glaucoma in the study eye. Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the nonstudy eye. Subjects who have had ocular surgery in the study eye within 3 months or in the fellow eye within 2 weeks prior to the screening visit. Women who are pregnant or breast feeding. Subjects who have participated in an investigational drug or device study within the last 30 days. Subjects previously randomized in this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>